S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 biotech powerhouses poised to thrive amid sector rebound
All the trading advice you’ve ever received boils down to this (Ad)
Broadcom falls into a buy-the-dip opportunity 
A 'soft landing' or a recession? How each one might affect America's households and businesses
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 biotech powerhouses poised to thrive amid sector rebound
All the trading advice you’ve ever received boils down to this (Ad)
Broadcom falls into a buy-the-dip opportunity 
A 'soft landing' or a recession? How each one might affect America's households and businesses
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 biotech powerhouses poised to thrive amid sector rebound
All the trading advice you’ve ever received boils down to this (Ad)
Broadcom falls into a buy-the-dip opportunity 
A 'soft landing' or a recession? How each one might affect America's households and businesses
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
10 e-commerce stocks to consider for long-term buys
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
How does the Consumer Price Index affect the stock market?
3 biotech powerhouses poised to thrive amid sector rebound
All the trading advice you’ve ever received boils down to this (Ad)
Broadcom falls into a buy-the-dip opportunity 
A 'soft landing' or a recession? How each one might affect America's households and businesses
All the trading advice you’ve ever received boils down to this (Ad)
Closing prices for crude oil, gold and other commodities
Carrier Global, Marathon Oil rise; RH, Newmont fall, Friday, 12/8/2023

RXi Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RXII)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$0.88
$1.02
50-Day Range
$0.36
$0.50
52-Week Range
$0.31
$7.70
Volume
478,691 shs
Average Volume
1.73 million shs
Market Capitalization
$4.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

RXII stock logo

About RXi Pharmaceuticals Stock (NASDAQ:RXII)

Phio Pharmaceuticals Corp. is a biotechnology company, which engages in the development of immuno-oncology therapeutics that addresses unmet medical needs. Its clinical product candidate includes RXI-109, an RNAi compound developed for the reduction of dermal scarring in planned surgeries. The company was founded on September 8, 2011 and is headquartered in Marlborough, MA.


RXII Stock News Headlines

Rex International Holding Ltd (RXI.SG)
Galena's Breast Cancer Vaccine Doomed to Fail
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Q4 2022 Catalyst Pharmaceuticals Inc Earnings Call
iShares Global Consumer Discretionary ETF (RXI)
RXi Pharmaceuticals CHART
RXi Pharmaceuticals (RXII) - Income Statement
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology
Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com
7 Firms Developing RNAi Drugs
See More Headlines
Receive RXII Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RXi Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/14/2018
Today
12/09/2023

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RXII
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-12,450,000.00
Net Margins
-4,990.20%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10,000.00
Book Value
$0.77 per share

Miscellaneous

Free Float
N/A
Market Cap
$4.08 million
Optionable
Not Optionable
Beta
2.07
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Gerrit Dispersyn
    President, Chief Executive Officer & Director
  • James Cardia
    Vice President-Business Operations
  • Caitlin Kontulis
    Secretary, VP-Finance & Administration
  • Simon Fricker
    Vice President-Research














RXII Stock Analysis - Frequently Asked Questions

How were RXi Pharmaceuticals' earnings last quarter?

RXi Pharmaceuticals Co. (NASDAQ:RXII) posted its earnings results on Tuesday, August, 14th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.16. The biotechnology company had revenue of $0.06 million for the quarter, compared to analyst estimates of $0.02 million. RXi Pharmaceuticals had a negative net margin of 4,990.20% and a negative trailing twelve-month return on equity of 412.15%.

When did RXi Pharmaceuticals' stock split?

RXi Pharmaceuticals's stock reverse split before market open on Monday, January 8th 2018. The 1-10 reverse split was announced on Friday, January 5th 2018. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 5th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of RXi Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other RXi Pharmaceuticals investors own include Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Auris Medical (EARS), Endologix (ELGX), Idera Pharmaceuticals (IDRA), Synergy Pharmaceuticals (SGYP), Anavex Life Sciences (AVXL), Micron Technology (MU) and

This page (NASDAQ:RXII) was last updated on 12/9/2023 by MarketBeat.com Staff

My Account -